Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Cancer Metastatic × Vemurafenib × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 7 Neoplasms 3 Skin Neoplasms 1 Skin Diseases 1 Neoplasm Metastasis 1 Colorectal Cancer Metastatic 1

Interventions

aflibercept 3 Irinotecan 2 Bevacizumab 2 XELOX 1 Vemurafenib 1 Panitumumab 1 Leucovorin 1 IFL protocol 1 Fluorouracil 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06008119 2025-09-18

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting

Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡